Pharmaceutical industry
The soaring costs of research and development, coupled with growing government efforts to control healthcare costs, are driving a surge in biopharmaceutical deal-making between U.S. and European companies. In the first half of 1995, pharmaceutical and biotechnology firms announced 44 cross-border deals worth $9.5 billion, a significant increase
Pharmaceutical industry
NeXstar Pharmaceuticals, Inc., a Boulder-based pharmaceutical company, announced its definitive agreement to acquire Supragen, Inc., a privately held biotechnology company specializing in therapeutics and vaccines for T-cell mediated diseases. The acquisition aims to strengthen NeXstar's research and development capabilities in immunology, infectious diseases, and oncology. Supragen's
Pharmaceutical industry
Signal Pharmaceuticals Inc. has announced the appointment of Carl F. Bobkoski as executive vice president, bringing his expertise in biopharmaceutical industry leadership to the company. Bobkoski joins Signal from Gensia Inc., where he held the same position and was a member of the board of directors. His experience in directing
Pharmaceutical industry
GeneMedicine, a Texas-based company, has partnered with Medi-Ject Corp. to develop needle-free injection devices for the delivery of therapeutic genes to specific tissues. This collaboration aims to enhance the delivery of gene therapies for various diseases and disorders. The partnership brings together GeneMedicine's cutting-edge gene technologies with Medi-Ject&
Pharmaceutical industry
Viagene, a biotechnology company in San Diego, has secured a non-exclusive license from Biogen for the use of hepatitis B virus (HBV) genes in gene therapy treatments for chronic HBV infection. According to Robert T. Abbott, President and CEO of Viagene, this license will enable the company to move into
Drugs
Genzyme Transgenics Corp. has announced the sale of its TSI Center for Diagnostic Products (CDP) to Intergen Company, LP, a leading manufacturer of reagents for the biopharmaceutical and diagnostics industries. The acquisition, valued at approximately $4 million in 1994 revenues, will enable Genzyme Transgenics to focus on its core business:
Pharmaceutical industry
Ciba-Geigy Ltd. and Chiron Corp. have completed a strategic partnership, combining the companies' strengths to discover, develop, manufacture, and market biotechnology and healthcare products globally. The partnership was announced November 21, 1994, and was finalized on January 4, 1995. As part of the agreement, Ciba-Geigy acquired approximately 20 million
Drugs
Genentech, a leading international biotechnology company, and Scios Nova, a biopharmaceutical company, have entered into a collaboration agreement to develop and commercialize Scios Nova's Auriculin (anaritide) for the treatment of acute renal failure (ARF). The partnership aims to leverage Genentech's expertise in clinical development and marketing
